Osivax Announces Vaccination of First Participant in First-in-Human Trial

Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033

• Phase 1 study to evaluate safety and immunogenicity of sarbecovirus (coronavirus) vaccine candidate, OVX033, at ascending dose levels
• The trial will enroll 48 participants in France

Lyon, France – February 15, 2024 –
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated in its new Phase 1 trial (NCT06128382) evaluating OVX033, a broad-spectrum sarbecovirus vaccine candidate. 

Lire le communiqué de presse